Skip to content

Study · Animal study (in vivo) · rat · 2024

14 results

The administration of Cerebrolysin elicits neuroprotective and neurorepair effects in an animal model of type 1 diabetes mellitus.

Espinoza I, Cabrera F, Morales-Medina JC, Gómez-Villalobos MJ, Flores G

Behavioural brain research17 Jun 2024Cited by 2 (Europe PMC)

PMID38897418 (opens in a new tab)DOI10.1016/j.bbr.2024.115115 (opens in a new tab)PepBankPUB-38897418
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, concurrent CBL administration did not alter STZ-induced hyperglycemia.

    In plain wordsIn rats with diabetes, concurrent CBL treatment did not alter high blood glucose.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeHyperglycemia with preventive treatment
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    STZ-induced hyperglycemia remained unaltered by the administration of CBL in both experimental conditions.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, delayed CBL administration did not alter STZ-induced hyperglycemia.

    In plain wordsIn rats with diabetes, delayed CBL treatment did not alter high blood glucose.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeHyperglycemia with delayed treatment
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    STZ-induced hyperglycemia remained unaltered by the administration of CBL in both experimental conditions.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, concurrent CBL treatment preserved neuronal morphology in PFC layer 3.

    In plain wordsIn rats with diabetes, concurrent CBL treatment preserved neuron structure in PFC layer 3.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePreventive PFC layer 3 neuronal morphology
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the first experimental condition, CBL treatment preserved the neuronal morphology in PFC layer 3, PFC layer 5 and the DG of the hippocampus, while also maintaining spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, concurrent CBL treatment preserved neuronal morphology in PFC layer 5.

    In plain wordsIn rats with diabetes, concurrent CBL treatment preserved neuron structure in PFC layer 5.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePreventive PFC layer 5 neuronal morphology
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the first experimental condition, CBL treatment preserved the neuronal morphology in PFC layer 3, PFC layer 5 and the DG of the hippocampus, while also maintaining spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, concurrent CBL treatment preserved neuronal morphology in the dentate gyrus.

    In plain wordsIn rats with diabetes, concurrent CBL treatment preserved neuron structure in the dentate gyrus.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePreventive DG neuronal morphology
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the first experimental condition, CBL treatment preserved the neuronal morphology in PFC layer 3, PFC layer 5 and the DG of the hippocampus, while also maintaining spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, concurrent CBL treatment maintained PFC-3 spine density.

    In plain wordsIn rats with diabetes, concurrent CBL treatment maintained PFC-3 spine density.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePreventive PFC-3 spine density
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the first experimental condition, CBL treatment preserved the neuronal morphology in PFC layer 3, PFC layer 5 and the DG of the hippocampus, while also maintaining spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, concurrent CBL treatment maintained dentate gyrus spine density.

    In plain wordsIn rats with diabetes, concurrent CBL treatment maintained dentate gyrus spine density.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePreventive DG spine density
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the first experimental condition, CBL treatment preserved the neuronal morphology in PFC layer 3, PFC layer 5 and the DG of the hippocampus, while also maintaining spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, concurrent CBL treatment maintained CA1 spine density.

    In plain wordsIn rats with diabetes, concurrent CBL treatment maintained CA1 spine density.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePreventive CA1 spine density
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the first experimental condition, CBL treatment preserved the neuronal morphology in PFC layer 3, PFC layer 5 and the DG of the hippocampus, while also maintaining spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, delayed CBL treatment induced neuronal repair in PFC-3.

    In plain wordsIn rats with diabetes, delayed CBL treatment induced neuronal repair in PFC-3.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDelayed PFC-3 neuronal repair
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, CBL induced neurorepair in neurons within the PFC-3, PFC-5 and CA1 regions of the hippocampus, along with an increase in spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, delayed CBL treatment induced neuronal repair in PFC-5.

    In plain wordsIn rats with diabetes, delayed CBL treatment induced neuronal repair in PFC-5.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDelayed PFC-5 neuronal repair
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, CBL induced neurorepair in neurons within the PFC-3, PFC-5 and CA1 regions of the hippocampus, along with an increase in spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, delayed CBL treatment induced neuronal repair in CA1.

    In plain wordsIn rats with diabetes, delayed CBL treatment induced neuronal repair in CA1.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDelayed CA1 neuronal repair
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, CBL induced neurorepair in neurons within the PFC-3, PFC-5 and CA1 regions of the hippocampus, along with an increase in spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, delayed CBL treatment increased PFC-3 spine density.

    In plain wordsIn rats with diabetes, delayed CBL treatment increased PFC-3 spine density.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDelayed PFC-3 spine density
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, CBL induced neurorepair in neurons within the PFC-3, PFC-5 and CA1 regions of the hippocampus, along with an increase in spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, delayed CBL treatment increased dentate gyrus spine density.

    In plain wordsIn rats with diabetes, delayed CBL treatment increased dentate gyrus spine density.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDelayed DG spine density
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, CBL induced neurorepair in neurons within the PFC-3, PFC-5 and CA1 regions of the hippocampus, along with an increase in spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, delayed CBL treatment increased CA1 spine density.

    In plain wordsIn rats with diabetes, delayed CBL treatment increased CA1 spine density.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDelayed CA1 spine density
    Study

    ratn: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, CBL induced neurorepair in neurons within the PFC-3, PFC-5 and CA1 regions of the hippocampus, along with an increase in spine density in the PFC-3, DG and CA1 hippocampus.
    3 context sentences
    Summary · context
    The administration of Streptozotocin (STZ) is a well-known animal model of insulinopenic type 1 DM in rats.
    Summary · context
    In the first experimental condition, STZ and CBL are administered at the same time to evaluate the potential preventive effect of CBL.
    Summary · context
    In the second experimental condition, CBL was administered two months after establishing the DM model to measure the potential neurorepair effect of CBL.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.